Gene · 6582
Papers2,540
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
241 to 260 of 2,540
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Cisplatin ototoxicity mechanism and antagonistic intervention strategy: a scope review. | Front Cell Neurosci | 2023 | 37323582 | PubTator, text mining | PubMed |
| Review and prospect of immune checkpoint blockade therapy represented by PD-1/PD-L1 in the treatment of clear cell renal cell carcinoma. | Oncol Res | 2023 | 37305384 | PubTator, text mining | PubMed |
| Discovery of New 2-Phenylamino-3-acyl-1,4-naphthoquinones as Inhibitors of Cancer Cells Proliferation: Searching for Intra-Cellular Targets Playing a Role in Cancer Cells Survival. | Molecules | 2023 | 37298798 | PubTator, text mining | PubMed |
| Molecular basis of polyspecific drug and xenobiotic recognition by OCT1 and OCT2. | Nat Struct Mol Biol | 2023 | 37291422 | PubTator, text mining | PubMed |
| Detection of potential drug-drug interactions for risk of acute kidney injury: a population-based case-control study using interpretable machine-learning models. | Front Pharmacol | 2023 | 37288110 | PubTator, text mining | PubMed |
| Interlaboratory Variability in the Madin-Darby Canine Kidney Cell Proteome. | Mol Pharm | 2023 | 37283406 | PubTator, text mining | PubMed |
| A ceRNA network-mediated over-expression of cuproptosis-related gene SLC31A1 correlates with poor prognosis and positive immune infiltration in breast cancer. | Front Med (Lausanne) | 2023 | 37275369 | PubTator, text mining | PubMed |
| A Korean Post-Marketing Study of Abacavir/Dolutegravir/Lamivudine in Patients with HIV-1. | Infect Chemother | 2023 | 37272234 | PubTator, text mining | PubMed |
| A Phase I Trial of the Dual MET Kinase/OCT-2 Inhibitor OMO-1 in Metastatic Solid Malignancies Including MET Exon 14 Mutated Lung Cancer. | Oncologist | 2023 | 37260332 | PubTator, text mining | PubMed |
| Lamivudine and Emtricitabine Dosing Proposal for Children with HIV and Chronic Kidney Disease, Supported by Physiologically Based Pharmacokinetic Modelling. | Pharmaceutics | 2023 | 37242665 | PubTator, text mining | PubMed |
| Permeability of Metformin across an In Vitro Blood-Brain Barrier Model during Normoxia and Oxygen-Glucose Deprivation Conditions: Role of Organic Cation Transporters (Octs). | Pharmaceutics | 2023 | 37242599 | PubTator, text mining | PubMed |
| Screening and Elucidation of Chemical Structures of Novel Mammalian α-Glucosidase Inhibitors Targeting Anti-Diabetes Drug from Herbals Used by E De Ethnic Tribe in Vietnam. | Pharmaceuticals (Basel) | 2023 | 37242539 | PubTator, text mining | PubMed |
| Electrolytes Play a Role in Detecting Cisplatin-Induced Kidney Complications and May Even Prevent Them-Retrospective Analysis. | Medicina (Kaunas) | 2023 | 37241122 | PubTator, text mining | PubMed |
| Glucose-Lowering Effects of Imeglimin and Its Possible Beneficial Effects on Diabetic Complications. | Biology (Basel) | 2023 | 37237539 | PubTator, text mining | PubMed |
| Transporter proteins knowledge graph construction and its application in drug development. | Comput Struct Biotechnol J | 2023 | 37235186 | PubTator, text mining | PubMed |
| Characterization of pharmacogenomic variants in a Brazilian admixed cohort of elderly individuals based on whole-genome sequencing data. | Front Pharmacol | 2023 | 37234706 | PubTator, text mining | PubMed |
| Bictegravir and Metformin Drug-Drug Interaction in People with Human Immunodeficiency Virus (HIV). | Infect Dis Rep | 2023 | 37218815 | PubTator, text mining | PubMed |
| Protective effects of esomeprazole against cisplatin-induced ototoxicity: an in vitro and in vivo study. | Aquat Toxicol | 2023 | 37210931 | PubTator, text mining | PubMed |
| Bictegravir/emtricitabine/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials. | EClinicalMedicine | 2023 | 37200995 | PubTator, text mining | PubMed |
| The Onco-Nephrology Field: The Role of Personalized Chemotherapy to Prevent Kidney Damage. | Cancers (Basel) | 2023 | 37190182 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/6582/papers?page=13